Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.39 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094573 | 0.83 | MMP13 (0.56) | BAZ2BBAZ2AALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL15318227 | 0.81 | HSD17B10 (0.45) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL8103043 | 0.81 | BAZ2B (0.53) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| Hydrochloric Acid SCHEMBL653318 | 0.80 | BAZ2B (0.51) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL20094572 | 0.78 | GAA (0.40) | ALDH1A1SMN1; SMN2LMNAGAATDP1 | |
| SCHEMBL19509025 | 0.78 | RAB9A (0.60) | ALDH1A1SMN1; SMN2LMNAGAAKDM4E | |
| SCHEMBL8102674 | 0.76 | BAZ2B (0.55) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL20094767 | 0.75 | DAO (0.49) | ALDH1A1LMNAGAATDP1KDM4E | |
| SCHEMBL4544324 | 0.74 | BAZ2B (0.67) | BAZ2BBAZ2AALDH1A1LMNAGAA | |
| SCHEMBL5202768 | 0.73 | BAZ2B (0.56) | BAZ2BBAZ2AALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME LLC | 2018-07-05 | — | — | US | disclosed |
| US-9944654-B2 | Nargenicin compounds and uses thereof as antibacterial agents | MERCK SHARP & DOHME CORP. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2712863-B1 | Novel inhibitors of bacterial biofilms and related methods | SEQUOIA SCIENCES INC (US) | 2014-10-22 | — | — | EP | disclosed |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | SEQUOIA SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186808-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | BAZ2B 3104/4885BAZ2A 3347/4885ALDH1A1 2012/4885 |
| US-20170305924-A1 | NARGENICIN COMPOUNDS AND USES THEREOF AS ANTIBACTERIAL AGENTS | NRDC, MME, NME2 | BAZ2B 3104/4885BAZ2A 3347/4885ALDH1A1 2012/4885 |
| US-20130274256-A1 | NOVEL INHIBITORS OF BACTERIAL BIOFILMS AND RELATED METHODS | BLVRB, MMP8, PGLS | BAZ2B 858/4885BAZ2A 789/4885ALDH1A1 3590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.